Somatic mutations in BRAF have been found in up to 10% of all NSCLC, more common in adenocarcinomas. E586 is located within the kinase domain of BRAF and E586K mutation has been shown to result in increased kinase activity. The predictive and prognostic significance of this mutation needs further study. Correlation with other laboratory and clinical findings is recommended.

BRAF is a serine/threonine kinase that plays a key role in the regulation of the mitogen-activated protein kinase (MAPK) cascade. Genetic alterations in BRAF are found in a large percentage of melanomas, thyroid cancers and histiocytic neoplasms as well as a small fraction of lung and colorectal cancers. Somatic mutations in BRAF have been found in up to 10% of all NSCLC, more common in adenocarcinomas. Genetic alterations of BRAF have been identified in 9% of lung adenocarcinomas. E586 is located within the kinase domain of BRAF and E586K mutation has been shown to result in increased kinase activity. The BRAF E586K mutation is likely oncogenic although the predictive and prognostic significance of this mutation needs further study. Correlation with other laboratory and clinical findings is recommended.